Literature DB >> 1291342

Sensitivity status of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine and sulfadoxine/pyrimethamine in a tribal population of District Sundargarh, Orissa.

S K Ghosh1, R S Yadav, V P Sharma.   

Abstract

In a malaria-endemic area of Orissa, wherein chloroquine has been in use for over thirty years, 58.3% (14/24) P. falciparum cases did not respond to single dose chloroquine (10 mg base/kg) in in-vivo test. With standard dose (25 mg base/kg) 31.2% cases (10/32) showed resistance, i.e. at RI (15.6%), RII (9.4%) and RIII (6.2%) levels. Standard dose was superior in response to the single dose therapy [p < 0.05; chi 2 (df 1) = 4.11]. Out of eight isolates tested in vitro, two showed resistance to chloroquine, five to sulfadoxine/pyrimethamine (SP) but all were sensitive to amodiaquine, quinine and mefloquine. Whereas the standard dose of chloroquine would be a better option in general, in resistant cases, SP, quinine and mefloquine offer an alternative drug choice. The implications of drug resistance in a malaria-control programme and the need to revise drug policy in India are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291342

Source DB:  PubMed          Journal:  Indian J Malariol        ISSN: 0367-8326


  3 in total

1.  Mutant pfcrt "SVMNT" haplotype and wild type pfmdr1 "N86" are endemic in Plasmodium vivax dominated areas of India under high chloroquine exposure.

Authors:  Prashant K Mallick; Hema Joshi; Neena Valecha; Surya K Sharma; Alex Eapen; Rajendra M Bhatt; Harish C Srivastava; Patrick L Sutton; Aditya P Dash; Virendra K Bhasin
Journal:  Malar J       Date:  2012-01-11       Impact factor: 2.979

2.  Prevalence and clinical manifestations of malaria in Aligarh, India.

Authors:  Umm-e Asma; Farha Taufiq; Wajihullah Khan
Journal:  Korean J Parasitol       Date:  2014-12-23       Impact factor: 1.341

3.  Battling the malaria iceberg with chloroquine in India.

Authors:  Vinod P Sharma
Journal:  Malar J       Date:  2007-08-07       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.